Pomalidomide in the Management of Relapsed Multiple Myeloma

References

• Becker N . Epidemiology of multiple myeloma. Recent Results Cancer Res.183, 25–35 (2011).
   PubMedGoogle Scholar
• Moreau P , San MiguelJ, LudwigHet al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.24(Suppl. 6), vi133–vi137 (2013).
   PubMed Web of Science ®Google Scholar
• Kumar SK , RajkumarSV, DispenzieriAet al. Improved survival in multiple myeloma and the impact of novel therapies. Blood111(5), 2516–2520 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar S , LeeJH, LahuertaJJet al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and Bortezomib: a multicenter international Myeloma Working Group Study. Leukemia26(1), 149–157 (2012).
   PubMed Web of Science ®Google Scholar
• San Miguel J , WeiselK, MoreauPet al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, Phase 3 trial. Lancet Oncol.14(11), 1055–1066 (2013).
   PubMed Web of Science ®Google Scholar
• Bartlett JB , DredgeK, DalgleishAG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat. Rev. Cancer4(4), 314–322 (2004).
   PubMed Web of Science ®Google Scholar
• Lacy MQ , McCurdyAR. Pomalidomide. Blood122(14), 2305–2309 (2013).
   PubMed Web of Science ®Google Scholar
• Gay F , MinaR, TroiaR, BringhenS. Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma. Expert Opin. Drug Metab. Toxicol.9(11), 1517–1527 (2013).
   PubMed Web of Science ®Google Scholar
• Sampaio EP , SarnoEN, GalillyR, CohnZA, KaplanG. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J. Exp. Med.173(3), 699–703 (1991).
   PubMed Web of Science ®Google Scholar
• Corral LG , HaslettPA, MullerGWet al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J. Immunol.163(1), 380–386 (1999).
   PubMed Web of Science ®Google Scholar
• Reddy N , Hernandez-IlizaliturriFJ, DeebGet al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol.140(1), 36–45 (2008).
   PubMed Web of Science ®Google Scholar
• Davies FE , RajeN, HideshimaTet al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood98(1), 210–216 (2001).
   PubMed Web of Science ®Google Scholar
• Lu L , PayvandiF, WuLet al. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc. Res.77(2), 78–86 (2009).
   PubMed Web of Science ®Google Scholar
• Le Gouill S , PodarK, AmiotMet al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood104(9), 2886–2892 (2004).
   PubMed Web of Science ®Google Scholar
• Anderson G , GriesM, KuriharaNet al. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1. Blood107(8), 3098–3105 (2006).
   PubMed Web of Science ®Google Scholar
• Escoubet-Lozach L , LinI-L, Jensen-PergakesKet al. Pomalidomide and lenalidomide induce p21(WAF-1) expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res.69(18), 7347–7356 (2009).
   PubMed Web of Science ®Google Scholar
• Mitsiades N , MitsiadesCS, PoulakiVet al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood99(12), 4525–4530 (2002).
   PubMed Web of Science ®Google Scholar
• Ito T , AndoH, SuzukiTet al. Identification of a primary target of thalidomide teratogenicity. Science327(5971), 1345–1350 (2010).
   PubMed Web of Science ®Google Scholar
• Zhu YX , BraggioE, ShiC-Xet al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood118(18), 4771–4779 (2011).
   PubMed Web of Science ®Google Scholar
• Krönke J , UdeshiND, NarlaAet al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science343(6168), 301–305 (2014).
   PubMed Web of Science ®Google Scholar
• Shi C-X , KortümKM, ZhuYXet al. Proteasome inhibitors block Ikaros degradation by lenalidomide in multiple myeloma. Haematologica100(8), e315–e317 (2015).
   PubMed Web of Science ®Google Scholar
• Shah JJ , StadtmauerEA, AbonourRet al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood126(20), 2284–2290 (2015).
   PubMed Web of Science ®Google Scholar
• Rychak E , MendyD, ShiTet al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br. J. Haematol.172(6), 889–901 (2016).
   PubMed Web of Science ®Google Scholar
• Schey SA , FieldsP, BartlettJBet al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J. Clin. Oncol.22(16), 3269–3276 (2004).
   PubMed Web of Science ®Google Scholar
• Lacy MQ , HaymanSR, GertzMAet al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol.27(30), 5008–5014 (2009).
   PubMed Web of Science ®Google Scholar
• Lacy MQ , HaymanSR, GertzMAet al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia24(11), 1934–1939 (2010).
   PubMed Web of Science ®Google Scholar
• Lacy MQ , AllredJB, GertzMAet al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood118(11), 2970–2975 (2011).
   PubMed Web of Science ®Google Scholar
• Richardson PG , SiegelD, BazRet al. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood121(11), 1961–1967 (2013).
   PubMed Web of Science ®Google Scholar
• Richardson PG , SiegelDS, VijRet al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized Phase 2 study. Blood123(12), 1826–1832 (2014).
   PubMed Web of Science ®Google Scholar
• Leleu X , AttalM, ArnulfBet al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide–refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood121(11), 1968–1975 (2013).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA , WeiselKC, SongKWet al. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Haematologica100(10), 1327–1333 (2015).
   PubMed Web of Science ®Google Scholar
• San Miguel JF , WeiselKC, SongKWet al. Impact of prior treatment and depth of response on survival in MM-003, a randomized Phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. Haematologica100(10), 1334–1339 (2015).
   PubMed Web of Science ®Google Scholar
• Song KW , DimopoulosMA, WeiselKCet al. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. Haematologica100(2), e63–e67 (2015).
   PubMedGoogle Scholar
• Weisel K , DimopoulosM, SongKWet al. Pomalidomide and low-dose dexamethasone improves health-related quality of life and prolongs time to worsening in relapsed/refractory patients with multiple myeloma enrolled in the MM-003 randomized Phase III trial. Clin. Lymphoma Myeloma Leuk.15(9), 519–530 (2015).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA , LeleuX, PalumboAet al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia28(8), 1573–1585 (2014).
   PubMed Web of Science ®Google Scholar
• Leleu X , KarlinL, MacroMet al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. Blood125(9), 1411–1417 (2015).
   PubMed Web of Science ®Google Scholar
• Touzeau C , MoreauP. How I treat extramedullary myeloma. Blood127(8), 971–976 (2016).
   PubMed Web of Science ®Google Scholar
• Short KD , RajkumarSV, LarsonDet al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia25(6), 906–908 (2011).
   PubMed Web of Science ®Google Scholar
• Li Z , QiuY, PersonettDet al. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS ONE8(8), e71754 (2013).
   PubMed Web of Science ®Google Scholar
• Weisel KC , DimopoulosMA, MoreauPet al. Analysis of renal impairment in MM-003, a Phase 3 study of pomalidomide +low-dose dexamethasone vs high-dose dexamethasone in refractory or relapsed andrefractory multiple myeloma. Haematologica doi: 10.3324/haematol.2015.137083 (2016) ( Epub ahead of print).
   Google Scholar
• Siegel DS , WeiselKC, DimopoulosMAet al. Analysis of pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma with vs without moderate renal impairment. Blood126(23), 3031–3031 (2015).
   Google Scholar
• Ramasamy K , DimopoulosMA, van de DonkNWCJet al. Safety of treatment (Tx) with pomalidomide (POM) and low-dose dexamethasone (LoDEX) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM) and renal impairment (RI), including those on dialysis. Blood126(23), 374–374 (2015).
   Google Scholar
• Richter J , BiranN, DumaN, VesoleDH, SiegelD. Safety and tolerability of pomalidomide-based regimens (pomalidomide–carfilzomib–dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series. Hematol. Oncol. doi: 10.1002/hon.2290 (2016) ( Epub ahead of print).
   Google Scholar
• Larocca A , MontefuscoV, BringhenSet al. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter Phase 1/2 open-label study. Blood122(16), 2799–2806 (2013).
   PubMed Web of Science ®Google Scholar
• Baz RC , MartinTG, LinH-Yet al. Randomized multicenter Phase II study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood doi: 10.1182/blood-2015-11-682518 (2016) ( Epub ahead of print).
   Google Scholar
• Lacy MQ , LaPlantBR, LaumannKMet al. Pomalidomide, bortezomib and dexamethasone (PVD) for patients with relapsed lenalidomide refractory multiple myeloma (MM). Blood124(21), 304–304 (2014).
   Google Scholar
• Richardson PG , HofmeisterC, RajeNSet al. A Phase 1, multicenter study of pomalidomide, bortezomib, and low-dose dexamethasone in patients with proteasome inhibitor exposed and lenalidomide-refractory myeloma (Trial MM-005). Blood126(23), 3036–3036 (2015).
   Web of Science ®Google Scholar
• Shah J , NiesvizkyR, StadtmauerEet al. Oprozomib, pomalidomide, and dexamethasone (OPomd) in patients (Pts) with relapsed and/or refractory multiple myeloma (RRMM): Initial results of a Phase 1b study (NCT01999335). Blood126(23), 378–378 (2015).
   PubMedGoogle Scholar
• Voorhees PM , MulkeyF, HassounHet al. Alliance A061202. a Phase I/II Study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: Phase I results. Blood126(23), 375–375 (2015).
   Google Scholar
• Chari A , LonialS, SuvannasankhaAet al. Open-label, multicenter, Phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma. Blood126(23), 508–508 (2015).
   PubMed Web of Science ®Google Scholar
• Badros AZ , KocogluMH, MaNet al. A Phase II study of a anti-PD-1 antibody pembrolizumab, pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM). Blood126(23), 506–506 (2015).
   Web of Science ®Google Scholar
• Stewart AK , RajkumarSV, DimopoulosMAet al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med.372(2), 142–152 (2015).
   PubMed Web of Science ®Google Scholar
• Atanackovic D , LuetkensT, KrögerN. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. Leukemia28(5), 993–1000 (2014).
   PubMed Web of Science ®Google Scholar
• Lonial S , VijR, HarousseauJ-Let al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol.30(16), 1953–1959 (2012).
   PubMed Web of Science ®Google Scholar
• Lonial S , DimopoulosM, PalumboAet al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med.373(7), 621–631 (2015).
   PubMed Web of Science ®Google Scholar